Polling Questions


< All Questions
According to the webcast:

with James G. Pfaus, PhD, IF
The melanocortin agonist bremelanotide has shown to modulate dopamine release by which of the following mechanisms:
 Activating dopamine release in the pre optic area (POA)
 Activating dopamine release in the nucleus accumbens (NAc)
 Activating dopamine release in the ventromedial nucleus (VMN)
 All of the above
 
 

Your answers are confidential and will be used for educational purposes only.

Submit